Becton, Dickinson and Co (NYSE:BDX) on Thursday reported third-quarter adjusted earnings of $3.23 per share, beating the consensus of $3.14.
The medical technology company reported sales of $4.983 billion, surpassing the Wall Street estimate of $4.887 billion.
Sales jumped 5.4% year over year (+4.4 on constant currency).
The company said on its earnings call that the growth reflects broad-based growth across the portfolio and disciplined execution through a dynamic environment.
Revenue Growth Across Key Medical Units
In the Medication Delivery Solutions division, total revenue reached $1.164 billion, up 2.8%, driven by U.S. commercial execution and market share expansion in Vascular Access Management, despite headwinds from volume-based procurement in China.
Specimen Management revenue grew 8.7% to $511 million, lifted by market share gains in BD Vacutainer products and competitor supply disruptions.
Additionally, Medication Management Solutions generated $915 million, up 3% behind double-digit dispensing momentum and strength in BD Rowa.
Patient Monitoring And Biopharma Expand
Advanced Patient Monitoring revenue surged 10.9% to $309 million, supported by Smart Recovery products, growing adoption of Acumen IQ Cuff and Acumen IQ Sensor, and solid consumable demand.
Meanwhile, Biopharma systems achieved 6.6% growth to $670 million, driven by double-digit growth in Biologics due to continued strength in GLP-1 offerings, partially offsetting lower market demand for vaccine products.
Interventional Segment Delivers Gains
Peripheral Intervention revenue rose 7.8% to $552 million, led by Oncology gains following the launch of the EnCor EnCompass Biopsy System and demand for the Rotarex Atherectomy System.
Urology & Critical Care revenue rose 4.2% to $440 million on double-digit PureWick adoption across home care settings, while Surgery revenue grew 7% to $422 million behind Infection Prevention and Advanced Tissue Regeneration.
“Our first full quarter as New BD demonstrates the early benefits of a more focused MedTech company, with strong momentum across our key growth platforms, continued innovation and further progress through BD Excellence,” said Tom Polen, chairman, CEO and president of BD.
“We remain focused on disciplined execution, advancing our key growth platforms, expanding margins and allocating capital strategically to drive sustainable growth and long-term shareholder value,” Polen said.
Citing broad-based momentum, the company revised its full-year fiscal 2026 adjusted earnings per share guidance from $12.52-$12.72 to $12.62-$12.72, compared to the consensus of $12.61.
BDX Price Action: Becton Dickinson shares were up 3.91% at $177.33 at the time of publication on Thursday, according to Benzinga Pro data.
Photo via Shutterstock